Efficacy of probiotics adjuvant therapy of allergic rhinitis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20240528002

Enrollment

104

Registered

2024-05-28

Start date

2023-04-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

efficacy of probiotics in treatment of allergic rhinitis allergic rhinitis,rhinitis,probiotics,efficacy

Interventions

Probiotics capsule 500 mg oral dialy dose for 8 weeks ,Placebo capsule 500 mg oral dialy dose for 8 weeks

Experimental Dietary Supplement,Experimental No treatment

Probiotics,Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-60 years 2. Confirm diagnosis of allergic rhinitis

Exclusion criteria

Exclusion criteria: 1.chronic rhinosinusitis with or without nasal polyp 2.nasal mass or nasal cancer or sinus cancer 3.petient with adverse effect of probiotics 4.pregnancy or lactating woman 4.caution with probiotic e.g.immunocompromise, prosthetic heart valves, impaired intestine function, central venous catheter, jejunostomy, broad-spectrum antimicrobials and poorly control diabetes mellitus

Design outcomes

Primary

Measure	Time frame
to study the efficacy of probiotics in treatment allergic rhinitis comparison with placebo controlled 8 weeks using Visual analogue scale (VAS) , Rhinitis control assessment test (RCAT),and Total nasal symptom score (TNSS)	—

Secondary

Measure	Time frame
Comparison the quality of life and side effect of probiotics in treatment allergic rhinitis 8 weeks Using rhinoconjunctivitis quality of life questionaire (RQLO)	—

Countries

Thailand

Contacts

Public ContactPanuwat Wongwattana

Srinakharinwirot university

panuwatw@gmail.com0909691366

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026